Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C

Liver International

Volumn 32, Issue 4, 2012, Pages 622-628

  Verveer, Claudia ^a   Zondervan, Pieter E ^a   Ten Kate, Fibo J W ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a   de Knegt, Robert J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CHB; CHC; Fibrosis; Liver; Non invasive; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; IRON;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; ELASTOGRAPHY; FATTY LIVER; FEMALE; GENDER; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; VIRUS LOAD;

AGE FACTORS; ALANINE TRANSAMINASE; ALCOHOL DRINKING; BIOPSY; BODY MASS INDEX; ELASTICITY IMAGING TECHNIQUES; FEMALE; FRANCE; GENOTYPE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HISTOLOGICAL TECHNIQUES; HUMANS; LIVER CIRRHOSIS; MALE; PLATELET COUNT; PROSPECTIVE STUDIES; ROC CURVE; SEX FACTORS; VIREMIA;

EID: 84858231170     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02663.x     Document Type: Article

References (47)

1. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on Hepatitis B virus and cirrhosis. Hepatology 1995; 21: 77-82.
2. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl. 1): S3-25.
3. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8.
4. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
5. de Jongh FE, Janssen Hl, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
6. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656-66.
7. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-93.
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
9. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
10. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
11. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
12. Buster EH, van Erpecum KJ, Schalm SW, et al. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Neth J Med 2008; 66: 292-306.
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
14. Wong SN, Lok AS. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12.
15. Iun F. [Methodical recommendations of Asian-Pacific Association for Studying the Liver (APASL) concerning treatment of the viral hepatitis B (HBV)]. Eksp Klin Gastroenterol 2008; 6: 116-19.
16. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
17. Persico M, Palmentieri B, Vecchione R, Torella R, de SI. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol 2002; 97: 491-2.
18. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
19. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-32.
20. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
21. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986; 2: 165-73.
22. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118: 150-3.
23. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993l; 118: 96-8.
24. Castera L, Nègre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30: 1529-30.
25. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
26. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
27. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
28. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
29. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
30. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
31. Oliveri F, Coco B, Ciccorossi P, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008; 14: 6154-62.
32. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-103.
33. Zhang YG, Wang BE, Wang TL, Ou XJ. Assessment of hepatic fibrosis by transient elastography in patients with chronic hepatitis B. Pathol Int 2010; 60: 284-90.
34. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-9.
35. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4.
36. Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002-7.
37. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48: 1718-23.
38. Sagir A, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-5.
39. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
40. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-35.
41. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
42. Marcellin P, De Ledinghen V, Dhumeaux D, et al. Non-invasive measurement of liver fibrosis in chronic hepatitis B using FibroScan (Abstract). Hepatology 2005; 42: 715A.
43. Castera L, Foucher J, Bernard PH, et al. Transient elastography (FibroScan) and Fibrotest to assess liver fibrosis in inactive hepatitis B carriers: a prospective controlled study (Abstract). Hepatology 2006; 44: 489A.
44. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
45. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 1288-93.
46. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
47. Kim SU, Kim do Y, Park JY, et al. How can we enhance the performance of liver stiffness measurement using fibroscan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010; 44: 66-71.